Breast cancer chemoprevention
Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indic...
| Auteurs principaux: | , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Frontiers Media S.A.
2011-12-01
|
| Collection: | Oncology Reviews |
| Sujets: | |
| Accès en ligne: | http://www.oncologyreviews.org/index.php/or/article/view/130 |